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A B S T R A C T
The aim of our cross-sectional study was to investigate the factors that affected Hepatitis-B Vaccination (HBV) knowl-
edge of the nurses and midwives, serving at various medical facilities as part of the primary healthcare services in
Konya, Turkey. The study was conducted during March 01 – 31, 2004, including 127 consentient nurses and midwives
(out of 161) serving at 22 different healthcare centers in the region. In the survey, their source of information with re-
gards to HBV vaccination varied from continuing education programs (37%) to book or brochure reading (11.8%), and
their formal nursing education (11%). A statistically significant relationship was found between the number of years em-
ployed in this profession and knowledge of Hepatitis markers that are done prior to the beginning of vaccination calen-
dar (p=0.01) (p<0.05). Majority (74.8%) of the participants reported that they gave information to families about poten-
tial side effects of HBV vaccination. In conclusion we have suggested that a special training program should be given to
nurses and midwives that included topics like Hepatitis markers, vaccine administration techniques, doses, proper re-
cord taking, briefing individuals and families.
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Introduction
With a chance to repeat itself and eventually become
chronic, the HBV infection is a common and very danger-
ous disease that is considered to be one of the most sig-
nificant viral infections today which causes high morbid-
ity and mortality all around the world1–4. Showed at the
studies carried out in Taiwan, the patients having chro-
nic HBV infection were found to have greater tendencies
in developing chronic liver disease, and their risk of
hepato-cellular carcinoma were found to be increased by
100 or even higher1. Nearly 5% of the world population
(300M) has chronic HBV infection that causes chronic
Hepatitis, cirrhosis and hepato-cellular carcinoma1,4–8. It
is estimated that active chronic Hepatitis develops in the
25% of carriers3. Every year 500,000 to 1 million people
dies of the HBV related liver diseases, such as cirrhosis
and hepato-cellular carcinoma1.
In our country, the prevalence rate of infection is
20–25% and carrier rate is 5–14%. The risk of developing
a chronic carrier state following an acute infection is in-
versely proportional to the age at which the infection
took place; for instance, that risk is as high as 90% in the
newborn period6. In 1–2% of the cases with acute Hepati-
tis infection, fulminant Hepatitis develops. In infants,
the symptoms of liver failure (encephalopathy, coagula-
tion defects, cerebral edema, etc.) are observed in most of
the cases. The mortality rate in fulminant Hepatitis is
about 60–90%6.
The long term goal of the immunization is the global
eradication of disease, and preventing the occurrences of
disease on more people and societies is the short term
goal9. Therefore, the eradication of HBV infection should
be one of the highest priorities in public healthcare10.
Principally, the healthcare professionals should perform
immunoprophylaxis through active and passive immuni-
zation regarding to healthcare services of infants, chil-
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dren, adolescents and adults over extended periods of
time, in order to reach these goals9.
Material and Methods
This is a cross-sectional study conducted in March
01–31, 2004 in Konya, in order to examine the HBV vac-
cination-related knowledge and practices of the nurses
and midwives serving at the primary healthcare services
in Konya province, and to determine any affecting fac-
tors.
The target population of the study consists of 161
nurses and midwives, serving at 22 healthcare centers
around the city of Konya, from which 127 of them agreed
to participate (78.8% participation).
The questionnaire was developed after a review of
technical literature1,5,6,9. It was tested in a pilot study
with 10 individuals, those who would be later excluded in
the study, and all necessary revisions were made. The
questionnaire had 34 questions including 7 about the de-
mographic characteristics of nurses and midwives, and
27 questions about the Hepatitis B vaccinations regard-
ing to its knowledge and practical implementations.
There were open-ended questions about the storage con-
ditions of Hepatitis B vaccines, about the place of the
vaccination box, about the temperature at which the vac-
cines should be kept, about the tests needed to be che-
cked before starting the vaccination schedule, about the
information regarding HBV diagnostic tests and the fac-
tors affecting immunization, induced by vaccination.
The data were collected by going to these clinics and
completing the survey in face-to-face interviews. Permis-
sion to conduct the study was obtained from the directors
of clinics and verbally from the participants.
The study data were evaluated using descriptive sta-
tistics and c2 on our computers (SPSS for Windows 10.0).
The arithmetic means were shown with standard deviation.
Results
In the analysis of socio-demographic characteristics of
participating nurses and midwives it was determined
that 67 (52.8%) were graduates of a medical vocational
high school, 55 (43.3%) were graduates of nursing associ-
ate degree programs, 4 (3.1%) had bachelor’s degree in
nursing and only one (0.8%) had a master’s degree in
nursing. The length of employment for both midwives
and nurses was 11.88±6.25 years (range 2–37). Their av-
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TABLE 1
DISTRIBUTION OF HBV DIAGNOSTIC TEST INFORMATION AND KNOWLEDGE ABOUT HBV VACCINE AND PRACTICES OF NURSES
AND MIDWIVES WHO WORK IN KONYA PROVINCIAL CENTER NEIGHBORHOOD PRIMARY CARE CLINICS
N %
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erage age was found to be 31.68±6.15 years (range
22–55). 120 of them (94.5%) were married, 7 (5.5%) were
single. The majority also had children with 108 nurses
and midwives (85.0%), among whom 51 (47.2%) of them
had two children, 47 (43.6%) had one children and 10
(9.2%) had three children.
The distribution about answers regarding to the HBV
diagnostic tests (such as whether or not they had done
the analysis – and if so, who that person had been) is
shown in Table 1, given by the nurses and midwives »then«
serving at various primary healthcare clinics in Konya.
There were refrigerated vaccine cabinets in every pri-
mary healthcare clinic inferior to the Konya province.
Distribution of data regarding to knowledge of nurses
and midwives about the storage conditions of Hepatitis
vaccine, are shown in Table 1.
The HBV vaccination knowledge of nurses and mid-
wives were assessed both in theory (Table 1) and on the
implementation level (Table 2, Table 3). Nearly, all of the
participating nurses and midwives (123, 96.8%) stated
that they had paid attention to the first opening date of
the vaccines, 94 (74%) stated they had marked the time
of opening on the vials, and 120 (94.5%) told they had
looked for the vaccine expiration date before using. In
addition, 50 (39.4%) of the participants stated that they
had always read the vaccine prospectus, 11 (8.7%) stated
that they had recorded the commercial brand name, and
18 (14.2%) indicated they had checked the records for
brand name about the earlier use of vaccine.
Among the participants, 12 (9.4%) of them stated that
they had told brand name to the family, 10 (7.9%) stated
that they had asked to the family of that name when no
records had been available, and 117 (92.1%) specified the
period between two vaccinations as »at least« 4 weeks.
The participating nurses and midwives were asked
about their source of information regarding to HBV vac-
cination, also asked whether they had lacked of any par-
ticular knowledge, and if yes, what it had been, as shown
in Table 3.
Half of the participants (64, 50.4%) indicated that
they had lacked the information regarding to source of
knowledge about HBV vaccine administration, whether
or not they needed information, and, if so, what kind of
information about which they wanted to learn are shown
in Table 3. The same number of nurses and midwives
(64, 50.4%) also revealed that they had lacked the knowl-
edge of factors that affect immunization, therefore, leaving
the remaining half (63, 49.6%) who only knew about it.
The participants were asked what information they
had given to families as briefing right after vaccination;
95 (74.8%) stated that they had been informing the fami-
lies about the potential side-effects, 10 (7.9%) stated they
had told them they would need to have their Hepatitis
markers checked in five years, 8 (6.3%) indicated that
they had informed the families about vaccination sched-
ule, and 14 (11.0%) stated that they hadn’t committed to
any such briefings.
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TABLE 2
DISTRIBUTION OF NURSES’ AND MIDWIVES’ KNOWLEDGE ABOUT HBV VACCINE ADMINISTRATION
N %
According to what is the hepatitis vaccination dose determined
It is standard, it does not change
According to the age (months/years) of the child
According to the vaccine drug insert information
















Knowledge about Hepatitis B side effects
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In addition, 62 participants (48.8%) told they hadn’t
conducted HBV test evaluations, 27 (21.3%) further ad-
mitted that they had no knowledge on this matter, at all
(Table 1). When asked who had done the Hepatitis test
analysis 77 (60.6%) responded the physician, 15 (11.8%)
responded infectious diseases specialists, and 27 (21.2%)
said they hadn’t known. Asked about the names of the
HBV diagnostic tests and its administration, 64 (50.4%)
of the participants answered as »HBsAg, anti-HBs« and
44 (34.6%) said, they had not known.
Discussion
Chronic HBV infection is a leading global health prob-
lem with affecting more than 350 million patients world-
-wide7, from which two people die in every minute. The
virus may cause liver cirrhosis, cancer and death. As the
treatment options are quite »limited« for infected pa-
tients, the British Medical Association believes that vac-
cination was the most effective method in prevention of
the HBV infection11. To accomplish avoiding disease, it is
recommended that all individuals in high risk group
along with the newborns, adolescents, and all of the chil-
dren up to 11–12 years who hadn’t been vaccinated, must
take vaccination6.
Hepatitis infections, in general, remain being top con-
cern among the healthcare personnel all around the
world4. The risks that they are already involved are of
the highest degree for the most educated, even the most
experienced hands. Any physical contact between the in-
fected body fluids and a simple cut on the skin, or inside
the mucous membrane may lead to full-spread infection
and pose a major threat against overall public health-
care. Despite the published guidelines and training prog-
rams, there is still an ongoing risk of »percutaneous ex-
posure« following accidental needlestick injuries6. Every
year, the healthcare workers constitute the 4% of the
new HBV infections in US, from which 200–300 of these
workers die from HBV-related complications11.
HBV is a lot more contagious than the AIDS virus by
a factor of 50–100. For instance, the cases involving HBV
in England and Wales have reportedly increased by 135%
from 1992 (489) to 2003 (1151)11. HBV spreads through
contact with blood or any other body liquids from an in-
fected person, from mother to baby during the carriage,
from child to child through open wounds, a shared toy
and saliva. Sharing razor blades and toothbrushes are
also a big risk11.
According to Maral et al. (1999), it was determined
that 28.3% of primary healthcare personnel had devel-
oped immunity against Hepatitis B following recovery
from their illnesses, 23.4% had been vaccinated against
Hepatitis B, and 1.7% had been determined to be anti-
-HCV positive. Clearly, these rates do not cover a big por-
tion12.
Suffice to say, any healthcare personnel dealing with
the HBV infections should be periodically educated about
viral Hepatitis and trained accordingly in an attempt to
overcome such incidents in working places. Similarly, in
a study by Turk et al. (2002), there was the mention of
serious need for healthcare staff in the hospitals to get
regular education about blood-borne illnesses13.
Diagnostic tests
Hepatitis is seen in four phases. These phases take
form depending on the genetic characteristics, presence
of other viruses, age and immunosuppression. The first
phase is the incubation period, involves the length of
time between the first contact with HBV and the rise of
aminotransferase levels. While this period takes 4–8 weeks
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TABLE 3
DISTRIBUTION OF NURSES’ AND MIDWIVES’ SOURCES OF AND REQUESTS FOR INFORMATION ABOUT HBV VACCINE
ADMINISTRATION
Sources of information about HBV N %
From physician–nurse
During formal nursing education




















What type of information about HBV vaccine do you want to learn
Protection and side effects
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for adults, it may take »years« for the newborn infants.
Most of the time, viral replication continues without
showing any of the disease symptoms; however, the se-
rum is positive for HBsAg, HBV-DNA and HbeAg6.
There are serological tests to detect HBsAg and
HBeAg just like there are assays aimed to detect antibod-
ies, such as anti-HBs, anti-HBc, IgM anti-HBc and those
against HBeAg. Furthermore, there are also hybridiza-
tion assays and gene amplification techniques in order to
detect the HBV DNA with its amount9.
HB surface antibodies can be detected during acute
infection period. IgM anti-HBc is quite specific to the di-
agnosis of an acute infection for adolescents and adults.
On the other hand, the infants developing prenatal infec-
tion usually do not have IgM anti-HBc. Those with
chronic infections of HBV have HBsAg, anti-HBc, and in
some cases anti-HBs in circulation. While both anti-HBs
and anti-HBc are detected in infected people, there is
only anti-HBs found in the people having HBV vacci-
nation9. Anti-HBs »negative« was defined as »<1.5 mLU/
mL«; a level of »1.5–10 mLU/mL« in pre-vaccination was
regarded as »insubstantial« and »>10 mLU/mL« in post-
-vaccination was defined as »reaction«14.
There is a correlation between the presences of HBeAg
in the blood serum, high titrations of HBV and stronger
infectivity. Besides, the HBeAg and HBV DNA tests are
proved to be useful candidate selection that is able to re-
ceive antiviral therapy, and at observing their reaction to
the therapy.
Knowing about the HBV diagnostic tests is an impor-
tant issue for healthcare personnel to carry on consulta-
tion. If they are not the ones who should be insightful,
then who shall be?
Vaccine storage & handling
The majority of the participants (86, 67.8%) knew
that the vaccines were needed to be stored between +2
and +8 °C, and 74 (58.3%) stated that vaccines should be
stored at the bottom shelf (Table 1). Nevertheless, these
rates were expected to be higher.
Improper storage of vaccines may result in immuniza-
tion failure. The recommended temperature for keeping
HBV vaccine is between 2–8 °C9. Once the vaccine is
frozen, it is spoiled9,15.
Vaccines freeze when refrigerator temperature drops
to zero degrees Celsius or below, especially when they
had a direct contact with an ice supply or exposure to
cold weather without sufficient protection15.
Proper storage and handling of vaccines is critical to
their efficacy and safety. Storage and handling instruc-
tions may be product specific. Therefore, it is important
to read and follow the manufacturer’s recommendations,
also known as the prospectus or the package insert, for
each product regarding: storage temperature, exposure
to light during storage, expiration/best use time, and
shaking of the product to assure uniform vaccine suspen-
sion. Maintaining vaccines at the appropriate tempera-
ture from arrival from manufacturer to patient adminis-
tration is a very important aspect of proper immunization
delivery programs.
Without doubt and without exceptions, the storing
place for vaccines »including the work hours« is refriger-
ator. Vaccines should be stored in the middle, not in the
door or against the back of the refrigerator. In the event
of refrigerator break-down or power failure, vaccines
should be removed promptly to an adequately refriger-
ated container. In either case, a working thermometer
should be kept inside the storing place and temperature
should be monitored frequently.
The vials
Paying attention to the best-use-time (expiration da-
te) is a fundamental issue in immunization. Having a
designated individual responsible for handling and stor-
age of vaccines is a recommended practice. Only one vial
should be opened at a time. Organizing vaccines accord-
ing to expiration date is key avoiding wastage by ensur-
ing that products with earlier expiration dates are used
before the products with later dates.
The opened vials should be kept on a separate tray so
»locating them« could be easier. Noticing the expiration
date on label, vaccines should be disposed properly in or-
der to prevent inadvertent uses. The first opening date of
each vial should be marked on its label9.
Sometimes, it seems to be an economical approach –
rather than recommendation, to keep using vaccines
starting from the opened flacons in accordance with the
»Cold Chain principle« instead of disposing them imme-
diately16.
In this study, almost all of the nurses and midwives
(123, 96.8%) were careful to check vial opening dates and
most of them (94, 74.0%) recorded that information onto
their labels. Considering the significance and vitality of
this fundamental issue, the result may seem satisfactory,
yet, it is not complete.
We have also observed almost all of the participants
paying attention to opening and expiration dates of the
vials, and some of them, in most cases very few, regularly
checking the prospectuses, taking fine records, making
archive searches, showing or designating all sorts of
proper actions. However, according to the American Aca-
demy of Pediatrics (AAP), records of the administration
site, administration techniques and the expiration date
are recommended to be taken upon each immunization9.
The National Childhood Vaccine Injury Act (NCVIA)
stipulates that the physicians administering vaccines
that are under the scope of Vaccine Injury Compensation
Program (VICP) must record the date of administration,
vaccine manufacturer, serial number and the vendor’s
contact information in the patient’s record9. It is our be-
lief that the health care personnel should be given thor-
ough information relevant to this issue.
Vaccination
When the nurses and midwives were asked how they
had determined the dosage for HBV vaccination, 43.3%
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answered that it was a standard dose which did not
change (Table 2). We expected that this rate would be
higher. A non-standard or low dose vaccination is not
considered to be valid and needs to be repeated appropri-
ately. The infant records that show late vaccination or
missed doses are needed to be marked in an informative
way such that it should tell us to complete the immu-
nization9.
The majority of the nurses and midwives (124, 97.4%)
knew that HBV vaccination was administered through
the deltoid muscle and 3 (2.4%) stated that was given in
the vastus lateralis muscle (Table 2). This is an expected
and encouraging result. Because the subcutaneous fatty
tissue is very thick in the gluteal region there is risk of
damaging the sciatic nerve, so the outer-upper quadrant
of the hips should not be used for vaccine administration.
Because otherwise has a lowered effectiveness in stimu-
lating the immune system, HBV vaccination should not
be given in the hips for any age groups9.
Due to adjuvant containing nature of HBV vaccine,
injection should be applied deep into the muscle tissues,
not any close to surface. Subcutaneous or intradermal
administrations should be avoided in order to prevent lo-
cal skin irritations, inflammation, granuloma formation
and necrosis9.
In this study 11 participants (8.7%) indicated that
they had recorded the commercial brand names of HBV
vaccines used in administration. Nevertheless, it is con-
sidered that the success of HBV vaccination did not depend
on the continuity of same brand, thus, a similar immune
response (through the products of different manufactur-
ers) was received without any significant difference9,14.
Predominant S including vaccine is a commonly used
one. Recently, it was reported that Pre S1 vs. Pre S2 anti-
genic vaccines were more successful at unresponsive
cases comparing to isolated-S antigenic vaccines. In a
study, it has been determined that recombinant S anti-
genic vaccines should be considered for healthy children
due to the availability of same antibody response in the
pediatric ages, along with their cheaper prices17.
Infant immunization
To question »how old the babies were when the HBV
vaccination was to be administered« the majority of par-
ticipants responded as »0–1 months« (115, 90.6%) (Table
1). This was a satisfactory result. Once children have
been immunized their bodies can fight those diseases if
they come into contact with them. If a child is not immu-
nized they will be at risk from catching the disease and
will rely on other people immunizing their children to
avoid becoming infected.
For protection, three separate doses of HBV vaccina-
tion are administered. According to generally applied
schedule, the first two vaccinations are given one month
apart, and a third one is given »6 months« after the first
administration. Infants are vaccinated at 0, 1 and 6
months6. It should be remembered that the cost of vacci-
nation for the newborn infants is less than the cost of a
possible medical treatment6,11.
With respect to the prevention of prenatal infections,
it is essential that all pregnant women should complete
serological detection tests for HBsAg, in order to early-
-determine which infants were to be introduced a post-
-exposure immunoprophylaxis9.
Because the immunity system of newborn is imma-
ture, 90% of the infected infants are likely to become
chronic asymptomatic HBV carriers. For the infants in-
fected by HBV at the prenatal period, there is consider-
ably a high risk of developing »chronic hepatitis«.
The rate of chronicization of Hepatitis B infection in
the children younger than 5 years old varies from 30–
60%. This rate is 3–10% in older children, adolescents
and adults. If that happens, Cirrhosis or hepato-cellular
carcinoma (liver cancer) develops when they become
adults6.
In accordance with the »HBV surveillance strategy
plan« prepared by World Health Organization (WHO)
and approved by the Advisory Committee on Immuniza-
tion Practices (ACIP), the Hepatitis B vaccination is ad-
ministered during childbirth. The purpose of this strat-
egy is to prevent the development of HBV infection
during the early stages of childhood and decrease the
number of chronic carriers within endemic societies. For
an infant to complete the triplet is more likely if HBV im-
munization is started at the childbirth7.
58 participants (45.7%) answered to the question about
the length of protection afforded by HBV vaccination as
lifelong and 35 (27.6%) eight years (Table 2). Today, hep-
atitis B immunization is applied with a recombinant vac-
cine that has a high reliability and effectiveness18.
The effectiveness of HBV vaccines (authorized in US)
with respect to HBV infections and clinical Hepatitis B in
the US is 90–95% on children and adults. It is reported
that protection was found to have a long-term effect. In
the long term studies carried on children and adults, im-
munization was shown to last for 12 years or even more
without a sign of decay, indicating a protection still-in-ef-
fect against HBV infections, even at undetectable levels
of anti-HBs concentrations9.
McGrane and Staines (2003) examined the nurses’
(N=120) understanding of HBV, their attitudes and their
acceptance of Hepatitis B vaccination. Results indicated
that their participants were aware of the etiology and
infectivity, and the acceptance rate was high19.
The leading reasons for such a high acceptance, or
participation included: free cost (81%), caring for clients
with HBV (78%), and benefits of the vaccine (75%)19.
Knowledge base
The nurses and midwives were asked about their
source of information about HBV vaccination, and 37%
responded as their in-service education programs and
training exercises, 11.8% indicated as reading books and
relevant material, and only 11% pointed out their formal
nursing education (Table 3). Considering the group who
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hadn’t acquired HBV information from nowhere (29.9%)
and those of others getting the knowledge thru informal
ways, the importance of university education and regular
training programs for healthcare staff is unquestionable,
thus, a proper education about viral diseases, immune
system, immunization, the HBV and HBV vaccination
should be presented, course material should be prepared
and distributed, and training exercises should be con-
ducted.
A statistically significant relationship was found be-
tween the number of years in profession and the knowl-
edge of Hepatitis markers prior to beginning of immuni-
zation calendar (p=0.01) (p<0.05). In addition, statis-
tically significant relations were found between the edu-
cation level of participants and their knowledge about
markers (p=0.04), HBV vaccination types, possible side
effects (p=0.00) and the factors affecting immunity (p<
0.05).
A statistically significant relation was found between
the participant ages and their knowledge about Hepatitis
markers before vaccination (the need for checking those
markers) and the minimum time between vaccine doses
(p=0.01) (p<0.05).
There were also statistically significant relations found
between the participant ages and their knowledge about
marking the vial opening time (p=0.03) and recording
the commercial brand names (p=0.02) (p<0.05). Statis-
tically significant relations were found between the years
of employment and knowledge of the optimum tempera-
ture for storing (p=0.00) and that with the Hepatitis
marker knowledge before starting vaccination calendar
(p=0.01) (p<0.05).
Post-vaccination
The NCVIA, enacted in 1986, stipulates that the cor-
responding risks and benefits should be explained to pa-
tients and parents if applicable9. In our study, the partici-
pants were asked what information they had given to the
families after vaccination. Although 74.8% stated they
had been informing the families about potential side-ef-
fects, the overall results in the questionnaire were far
from being satisfactory. Regarding to the family briefing
session held at post-vaccination by nurses and midwives
in this study, rate of education and content quality were
found to be quite low. While this is part of their job and
part of professions, the resulting situation leads to either
they were not aware of this job, or they did not know
about it. No matter what, this has to be improved.
Included in the new »Vaccine Information Sheets«
(VIS) there is a place for signatures indicating that the
patient or parents had »read and understood« what was
written. While asking for signature is at personnel’s own
discretion, the AAP suggests that the physicians’ records
should include whether or not the patient representa-
tives had received VIS, thus, been formally informed
about the matter9.
The WHO has recommended that every child should
be vaccinated in order to prevent infant deaths from vac-
cine preventable diseases. To this end, parents, as the
most versatile contributors to childhood vaccine sched-
ules, should be equipped with enough knowledge and
awareness on this very matter. They need to be encour-
aged to ask questions to be sure they had a clear under-
standing of the information conveyed. Healthcare person-
nel need to know how much the parents had comprehen-
ded about the vaccine that has been given to their children.
It is clear that the healthcare personnel’s knowledge
level about this subject must be at the required level.
Keeping that »the risk of infection decreases with ev-
ery successful immunization« on our mind, we concur
that the healthcare personnel ought to know well about
HBV diagnostic tests and the infection prevention meth-
ods so they could help the global cause in »big picture«
with increasing the public awareness by means of ade-
quate briefing and counseling for the patients and fami-
lies, those who would probably look for making the men-
tion and recommend vaccination as volunteers in the
first place. By all means, we should make sure the nurs-
ing staff is kept up-to-date and very well educated, start-
ing from their formal educations at the college.
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TEORIJSKA I PRAKTI^NA ZNANJA MEDICINSKIH SESTARA I PRIMALJA O CIJEPLJENJU
PROTIV VIRUSA HEPATITISA B (HBV): TRANSVERZALNO ISTRA@IVANJE U KONYI, TURSKA
S A @ E T A K
Cilj na{eg transverzalnog istra`ivanja bio je utvrditi ~imbenike koji su utjecali na znanje medicinskih sestara i pri-
malja o cijepljenju protiv hepatitisa B (HBV), slu`e}i na raznim zdravstvenim ustanovama, kao dio primarne zdrav-
stvene usluge u Konyi, u Turskoj. Istra`ivanje je provedeno tijekom o`ujka, 2004. godine, uklju~uju}i 127 suglasnih
medicinskih sestara i primalja (od ukupno 161) koje rade na 22 razli~ita zdravstvena centra u regiji. U anketi, njihov
izvor informacija o HBV cjepivima, variralo je od neprekinutog programa obrazovanja (37%), ~itanja knjiga ili bro{ura
(11,8%), i njihovog formalnog obrazovanja o skrbi (11%). Statisti~ki zna~ajna razlika je prona|ena izme|u broja godina
zaposlenih u ovoj struci i znanja o markerima hepatitisa koji su pripremljeni prije po~etka kalendara cijepljenja (p=
0,01) (p<0,05). Ve}ina (74,8%) ispitanika izjavilo je da je obiteljima pru`ilo informaciju o mogu}im nuspojavama cijep-
ljenja HBV. U zaklju~ku smo predlo`ili da se poseban program osposobljavanja treba omogu}iti medicinskim sestrama i
primaljama koji bi obuhva}ao teme kao {to su markeri hepatitisa, pravilne tehnike cijepljenja, doziranje, pravilno regi-
striranje cijepljenja, informiranje pojedinaca i obitelji.
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